Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

671 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison between AJCC 8th prognostic stage and UICC anatomical stage in patients with primary breast cancer: a single institutional retrospective study.
Tanaka R, Yamagishi Y, Koiwai T, Kono T, Fukumura-Koga M, Einama T, Yamasaki T, Sato K, Ueno H, Kishi Y, Tsuda H. Tanaka R, et al. Among authors: yamagishi y. Breast Cancer. 2020 Nov;27(6):1114-1125. doi: 10.1007/s12282-020-01115-x. Epub 2020 Jun 3. Breast Cancer. 2020. PMID: 32495291 Free PMC article.
Membrane mesothelin expression positivity is associated with poor clinical outcome of luminal-type breast cancer.
Suzuki T, Yamagishi Y, Einama T, Koiwai T, Yamasaki T, Fukumura-Koga M, Ishibashi Y, Takihata Y, Shiraishi T, Miyata Y, Iwasaki T, Shinto E, Sato K, Ueno H, Yamamoto J, Kishi Y, Tsuda H. Suzuki T, et al. Among authors: yamagishi y. Oncol Lett. 2020 Nov;20(5):193. doi: 10.3892/ol.2020.12055. Epub 2020 Sep 3. Oncol Lett. 2020. PMID: 32952662 Free PMC article.
Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients.
Einama T, Yamagishi Y, Takihata Y, Suzuki T, Yamasaki T, Hirose Y, Kobayashi K, Yonamine N, Fujinuma I, Tsunenari T, Koga M, Ishibashi Y, Nagata K, Shiraishi T, Nakazawa A, Iwasaki T, Shinto E, Kato K, Sato K, Ueno H, Kishi Y, Tsuda H. Einama T, et al. Among authors: yamagishi y. Biomark Res. 2021 Oct 29;9(1):78. doi: 10.1186/s40364-021-00335-3. Biomark Res. 2021. PMID: 34715925 Free PMC article.
Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging for Prediction of Metastasis to Sentinel and Nonsentinel Nodes in Patients with Clinically Node-Negative Breast Cancer.
Yamagishi Y, Yamasaki T, Ishida J, Moriya T, Einama T, Koiwai T, Fukumura-Koga M, Kono T, Hayashi K, Ueno H, Yamamoto J, Tsuda H. Yamagishi Y, et al. Ann Surg Oncol. 2020 Aug;27(8):2698-2710. doi: 10.1245/s10434-020-08269-0. Epub 2020 Mar 2. Ann Surg Oncol. 2020. PMID: 32124121 Free PMC article.
Different role of MSLN and CA125 co-expression as a prognostic predictor between perihilar and distal bile duct carcinoma.
Takihata Y, Einama T, Kobayashi K, Suzuki T, Yonamine N, Fujinuma I, Tsunenari T, Yamagishi Y, Iwasaki T, Miyata Y, Shinto E, Ogata S, Tsujimoto H, Ueno H, Kishi Y. Takihata Y, et al. Among authors: yamagishi y. Oncol Lett. 2021 May;21(5):414. doi: 10.3892/ol.2021.12675. Epub 2021 Mar 23. Oncol Lett. 2021. PMID: 33841575 Free PMC article.
Clinical Impact of Dual Time Point 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer.
Einama T, Yamagishi Y, Takihata Y, Konno F, Kobayashi K, Yonamine N, Fujinuma I, Tsunenari T, Kouzu K, Nakazawa A, Iwasaki T, Shinto E, Ishida J, Ueno H, Kishi Y. Einama T, et al. Among authors: yamagishi y. Cancers (Basel). 2022 Jul 28;14(15):3688. doi: 10.3390/cancers14153688. Cancers (Basel). 2022. PMID: 35954351 Free PMC article.
671 results